Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents
Published Date:April 8, 2015
Corporate Authors:Panel on Clinical Practices for the Treatment of HIV Infection (U.S.) ; Centers for Disease Control and Prevention (U.S.) ; National Institutes of Health (U.S.). Office of AIDS Research. Advisory Council.
Anti-HIV Agents/adverse Effects
Anti-HIV Agents/therapeutic Use
Antiretroviral Therapy, Highly Active/adverse Effects
Antiretroviral Therapy, Highly Active/Standards
Drug Resistance, Viral
HIV Infections/drug Therapy
Pregnancy Complications, Infectious/drug Therapy
Description:Antiretroviral therapy (ART) for the treatment of HIV infection has improved steadily since the advent of potent combination therapy in 1996. New drugs that offer new mechanisms of action, improvements in potency and activity even against multidrug-resistant viruses, dosing convenience, and tolerability have been approved. ART has dramatically reduced HIV-associated morbidity and mortality and has transformed HIV disease into a chronic, manageable condition. In addition, effective treatment of HIV-infected individuals with ART is highly effective at preventing transmission to sexual partners.1 However, less than one-third of HIV-infected individuals in the United States have suppressed viral loads,2 which is mostly a result of undiagnosed HIV infection and failure to link or retain diagnosed patients in care. Despite remarkable improvements in HIV treatment and prevention, economic and social barriers that result in continued morbidity, mortality, and new HIV infections persist.
Last updated April 8, 2015; last reviewed April 8, 2015.
Revisions to the May 1, 2014, version of the guidelines include key updates to several existing sections and the addition of two new tables. Significant updates are highlighted throughout the document.
Supporting Files:No Additional Files
You May Also Like: